Endpoints Webinars

Life sciences marketers work with long sales cycles and products that require market education — which make webinars one of the most essential tools in the biopharma demand generation toolbox. 

Endpoints webinars are a turn-key solution — let us handle the audience generation, content, marketing, and tech.

Upcoming Webinars

Project Optimus: Early-stage haste can lead to waste

The evaluation of pan-cancer and oncoRevealTM CDx panels to support localized NGS testing

The clinical trial recruitment crisis hits home

Advanced dosage forms: Tackling drug delivery challenges & addressing patient needs

The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval

Accelerate drug development with clinicogenomic RWE

past Webinars

A journey without a map: lessons in building an oncology powerhouse where innovation thrives

Changing the paradigm for colorectal cancer: Clinical practice & drug development

A crisis in rare disease: How the current investment landscape is stifling rare disease development

Why can’t we agree on how to define digital twins in healthcare?

Hit discovery with self-service DNA-encoded Libraries

Parkinson’s R&D: Have we finally reached a turning point?

Integrated clinical development and supply: Breaking down the early-development journey of a small molecule

Identify and quantify point mutations in circulating tumour DNA: The ddPCR approach™

Planning for CGT commercialization: It starts sooner than you think

Developing optimal biomarkers for cancer immunotherapy

Biology's modern LIMS for labs of the future

Pain R&D: Plenty of pain to go around, but who’s making gains?

Advanced plasmid technology: improving safety and performance​

How could an open access DNA-encoded library benefit your research?

New data: How ctDNA is evolving oncology patient management and drug development

Evolution of cell & gene therapy in China: the case for universal CAR-T

Public markets' impact on manufacturing advanced therapies

Mission critical: Cybersecurity

New biomarkers are remapping the world of cancer studies

Double your development speed: a new approach to viral vector design

Accelerating first-in-class and best-in-class programs using a large-scale digital chemistry strategy

Rethinking market access: Delivering on the promise of therapeutic innovation

Applying machine learning to increase clinical trial efficiency: a regulatory journey

Building a digital foundation for patient-centric trials

Data’s influence early in the commercialization process

How to create a stand-out customer experience for cell and gene therapies

Solving complex immunogenicity challenges

R&D changemakers: Building Resilience’s digital infrastructure for a modern R&D team

How can real-world clinico-genomics data optimize drug development?

The R&D challenge: What are the best practices in drug development today?

The role of Parkinson’s Disease biomarkers in drug development clinical trials

Metabolomics in drug discovery: The missing piece for multi-omics data

Making innovation matter by ensuring access to cancer care

The new psychedelic age in biotech

The phase 1 trial setup toolbox

Planning for the commercialization of advanced therapies

AI faces its moment of truth

Diagnostics from digital pathology: an AI solution to accelerate precision medicine

Different approaches to process development and manufacturing in gene therapy

How can biopharma deliver on the promise of precision medicine?

The pillars of research in 2035

The top 100 VCs in biotech 2022

Did you know Australia does toxicology?

Navigating your biopharma drug candidate through early and mid-stage clinical trials

The checkpoint debate is about to get real

Ensuring sample integrity from collection to analysis

CQV strategies that increase speed-to-market for gene therapy

Enterprise R&D technology adoption case study: Genentech

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Using external data to accelerate randomized controlled trials without introducing bias

State of the union for advanced medicines

CQV strategies to optimize cell therapy manufacturing

Innovations in clinical trial design with ctDNA MRD

Developing the next big vaccine technologies

Running decentralized trials at scale

mHealth innovation: identifying the best patient-centered technology for your trial needs

How biotechs have found success with University of Florida technologies

Changing the game: an examination of cutting-edge novel oncology screening tools

Scaling up a gene therapy manufacturing facility

A new class of startups is scouting for deals - on both sides of the Pacific

DEL like never before - 4th generation of DEL kits

Driving efficiencies through virtual trial solutions in Asia Pacific

After a decade of consolidation, who rules the CRO roost?

Concept to dosing: Challenges in new orphan drugs

Is the AI revolution empowering the scientist?

How Regeneron scaled its cloud to support millions of samples a year

Can changing one step change everything? Replacing your polishing step with a single-use solution

Pricing strategies for advanced therapies

HQ plasmid DNA: a case for phase dependent approaches to manufacturing

Non-clinical and clinical pathways for rapid vaccine development in Australia

Leading with data: tumor-informed ctDNA testing across cancer types

After the pandemic, antibody R&D remains key

Strategies for building a cell therapy manufacturing facility

The neurosciences comeback: After a lengthy chill, Big Pharma is warming back up to neuro

Recent key advances in autologous stem cell-derived therapies

Expedited clinical development strategies for China

Protein degradation: Looking back and moving forward

Enrolling a global study ahead of schedule (during a pandemic)

The big platform plays have been in vogue. But for how long?

Essential strategies for gene therapy - from assay development to CDx commercialization

Innovation in drug product manufacturing: how do we bring new therapies to patients faster?

Life science SPACs – the future of IPOs/crossover investing? A look at 2021/2022

Kantar Health on the most impactful trials at ASCO

Reinventing Harvest Technology: Single-stage chromatography clarification for recombinant protein therapeutic manufacturing

Reengineering CAR-T for solid tumors

Informed by the tumor: new data on the power of a personalized ctDNA assay

Deconvoluting inflammation and immunology for clinical trials

How scalable and intensified is your CAR-T process?

Improving endpoint selection in Alzheimer’s disease trials

Are we ready for the medicines of tomorrow? Creating the infrastructure for the era of genomic medicine

Plasmid DNA Insights: Expanded focus on CMC in gene & cell therapy development

Developing and using digital biomarkers

Transformative approaches to clinical development: Scaling adoption across the industry

Realizing the full potential of clinicogenomics

Hot topics in Immunoassay Bioanalysis - navigating the immunogenicity and biomarker requirements for clinical trials

The Great Debate: Internal vs. external manufacturing for advanced therapies

Predict placebo response using patient psychology to increase trial power

Can sponsors collect data in Expanded Access (EAPs) and Named Patient Programs (NPPs)?

Clinical trial diversity in the Covid-19 era — are we seeing a paradigm shift?

The benefits of running clinical trials in China

Where does your organization sit on the omnichannel maturity curve?

Flattening the 'valley of death:' New tools in the hunt for better preclinical R&D

Repurposing drugs for new indications: benefits and challenges

Leveraging APAC partnerships to de-risk clinical trials

Patient-First R&D: Why the patient experience should be at the center of clinical trial design

Navigating the path to the clinic and beyond for gene therapies

Beyond AAV 1.0

Enabling multidimensional tumor immunogenomics for advancing biomarker discovery

Breakthrough Technologies to Accelerate Biologic Drug Discovery, Cell Line Development and Biomanufacturability

How the World’s First Biolabs Client Portal GALEXI™ Delivers Real-Time Study Management for Biotechs

The Patient Voice in Rare Disease Research

Redefining conditioning for a new era of gene therapy

DEL Kits Special Event: A New Method of Hit Discovery

Optimizing Direct-to-Patient Clinical Supply for Decentralized Clinical Trials

Amgen’s BiTE® Platform and the Next Frontier in Immuno-Oncology

Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape

R&D in an age of Covid-19: Tackling the key issues around starting, or restarting an early-stage study

Solving hard go-to-market challenges

New Platform for Target-to-Hit: From Fragment Screen to Structure-based Drug Discovery

Introduction to Self-Service DNA-Encoded libraries (DELs)

Keeping Pace with Big Pharma - On A Start Up Budget

Putting AI in R&D

Managing Global Studies with Regional Partners

Faster, More Efficient Trials: Novel Trial Designs using Digital Twins

Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs

The Transformation of Clinical Trial Design and Operations: A Panel Discussion on COVID-19 as a Catalyst for Decentralized Trials

AI, Digital Twins, and the Future of Clinical Research

When cell and gene therapies surge to market, how resilient will your cell sourcing infrastructure be?

The Australian Early Phase Biosimilars Clinical Trial Landscape - How Agilex Biolabs and Nucleus Network Work Together

The FDA and Covid-19: New rules for the R&D road

Novel oncology trial designs with a personalized ctDNA assay

Derisking orphan drug programs in 2020 and beyond

A Clinical Investigator’s Perspective: Novel Oncology Therapy During & Beyond the COVID Pandemic

Home Nursing Support for Clinical Trials

Running First-in-human and Vaccines Studies in Australia

How Easy is it to Move your Clinical Trials to Australia?

Utilizing the immunoSEQ Assay in Clinical Trials

The Covid-19 challenge: Keeping the supply chain intact

Dealmaking in a time of coronavirus

Endpoints Editor John Carroll's Covid - 19 webinar series

Advancing Oncology Clinical Trials in Asia-Pacific

Asia-Pacific – a Global hub for Hepatology Clinical Trials

Perspectives on Partnering Post-Pandemic

Clinical Trial Continuity in Asia-Pacific during the COVID-19 Pandemic

The Australian Advantage: De-risk your early phase trials

Rapid Deployment of Remote Trials During Containment

RWD for R&D: Examples from Immunology, Rheumatology and Other Chronic Diseases

Designing a turnkey orphan drug program

The do’s and don’ts of managing a pivotal gene therapy trial

You've got that coveted accelerated regulatory pathway. Now what?

Developing better assays for biopharma with a CRO partner

Are you really ready for your end of phase 2 meeting?

How to run a Digital Trial and reduce time in development by 50%

Improving Clinical Trial Quality with Best Practices for E-Clinical Technology

Developing a digital therapeutics trial

The Experts: Real World Endpoints

Designing Next-Gen Oncology Trials

ctDNA as a biomarker for monitoring treatment response and molecular recurrence in early-stage and metastatic cancers

How to get the most out of your Phase I biologic study

The Alzheimer's Trials of the Future